XML 60 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Related-party Transactions (Details) - USD ($)
1 Months Ended
Jul. 22, 2019
Feb. 01, 2017
Jul. 31, 2019
Jul. 31, 2016
Dec. 31, 2019
Dec. 31, 2018
Celgene License Agreement            
Related Party Transaction [Line Items]            
Non-refundable upfront payment received for research agreement $ 50,000,000          
Celegene Collaborative Arrangement            
Related Party Transaction [Line Items]            
Non-refundable upfront payment received for research agreement       $ 225,000,000    
Series B-1 Convertible Preferred Stock | Celegene Collaborative Arrangement            
Related Party Transaction [Line Items]            
Issuances of convertible preferred stock (in shares)       10,448,100    
Issuances of convertible preferred stock       $ 36,100,000    
Celgene Corporation | Celgene License Agreement | Celgene License Agreement            
Related Party Transaction [Line Items]            
Non-refundable upfront payment received for research agreement     $ 50,000,000      
Reimbursable expenses due from Celgene         $ 700,000 $ 0
Celgene Corporation | Celgene Collaboration Agreement | Celegene Collaborative Arrangement            
Related Party Transaction [Line Items]            
Non-refundable upfront payment received for research agreement       $ 225,000,000    
Celgene Corporation | Celgene Collaboration Agreement | Series B-1 Convertible Preferred Stock | Celegene Collaborative Arrangement            
Related Party Transaction [Line Items]            
Issuances of convertible preferred stock (in shares)       10,448,100    
Issuances of convertible preferred stock       $ 36,100,000    
Celgene Corporation | IPO | Celgene Collaboration Agreement | Common Stock            
Related Party Transaction [Line Items]            
Stock converted upon completion of IPO (in shares)   2,831,463        
Affiliated Entity | Celgene Corporation | IPO | Celgene Collaboration Agreement | Common Stock            
Related Party Transaction [Line Items]            
Sale of stock, number of shares issued (in shares)   625,000        
Sale of stock, price per share (USD per share)   $ 16.00        
Proceeds from IPO, net of discounts, commissions, and other offering expenses   $ 10,000,000